News

The development follows the commissioning of the hydroxyurea manufacturing facility by Quality Chemical Industries Limited (QCIL) in Luzira, Kampala, where the…

Single dose safely corrected primate stem cells to levels considered curativeAn experimental, single-dose gene-editing therapy from Tessera Therapeutics…

AbstractSickle cell disease (SCD) is caused by a point mutation in the β-globin gene that promotes hemoglobin polymerization, leading to chronic hemolytic anemia,…

HighlightsWhat are the main findings?Gene therapy for sickle cell disease has progressed from lentiviral gene addition strategies to precise genome editing…

AbstractIntroduction: Sickle cell disease (SCD) is a genetic condition with serious complications, frequently necessitating emergency medical attention. This study…

Sickle Cell Anemia Testing and Screening Market was valued at USD 494.8 million in 2025 and is expected to reach USD 1,579 million by 2035, growing at a CAGR of 12.…

Fertility also improved, with 2 successful pregnancies after treatment: StudyNearly every person with sickle cell disease (SCD) who underwent a new regimen for stem…

Agios Pharmaceuticals AGIO executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in…

Despite rapid therapeutic advances in sickle cell disease, from red blood cell exchange to gene therapies, delivery remains constrained by infrastructure, geography…

AbstractIntroduction: Sickle cell disease is an inherited red blood cells disorder which leads to oxidative stress and resulting in the disturbance of energy…